Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Boehringer Ingelheim
Harvard Business School
Daiichi Sankyo
McKinsey
Express Scripts
Citi
Moodys
Fuji
Novartis

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206143

« Back to Dashboard

NDA 206143 describes CORLANOR, which is a drug marketed by Amgen Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the CORLANOR profile page.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ivabradine hydrochloride profile page.
Summary for 206143
Tradename:CORLANOR
Applicant:Amgen Inc
Ingredient:ivabradine hydrochloride
Patents:4
Pharmacology for NDA: 206143
Suppliers and Packaging for NDA: 206143
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CORLANOR ivabradine hydrochloride TABLET;ORAL 206143 NDA Amgen Inc 55513-800 55513-800-80 180 TABLET, FILM COATED in 1 BOTTLE (55513-800-80)
CORLANOR ivabradine hydrochloride TABLET;ORAL 206143 NDA Amgen Inc 55513-800 55513-800-60 60 TABLET, FILM COATED in 1 BOTTLE (55513-800-60)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Apr 15, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 15, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ SubscribePatent Expiration:Apr 17, 2026Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
Patent:➤ SubscribePatent Expiration:Apr 14, 2026Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
UBS
US Army
Colorcon
Cipla
Chubb
Farmers Insurance
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot